Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
@biogerontology
My posts are strictly personal, not reflective of positions or policies of Insilico Medicine, which disclaims any responsibility for my individual statements.
1.8K Following 44K Followers
Welcome to the Era of Longevity Biotechnology. The new Treehouse at Harvard is simply spectacular. Check out what awaits you next week:
I am happy to report that we just dosed our first patient in the pivotal Phase III trial. Please Wish Me Luck and Strong Sustained Efficacy! 🍀🤞
My dear friends, I am happy to report the publication of the most important paper in my life to date (we have several great papers coming out but this is very special). Tomorrow, I will present this paper for the first time at the Nature AI Healthcare in Paris and will post a longer post on this story and its broader implications for how to conduct clinical trials. Please read it and comment on it.
Many thanks to the great co-authors of the study and everyone who contributed. Many thanks to the many reviewers (friendly and unfriendly) for spending so much time and helping make it better.
Link in the comments.
Show more
🧪 NEW SOTA in chemical synthesis
Building molecules is hard. There are countless possible routes, but only some actually work. We trained a 2.6B LFM model by @liquidAI in #MMAIGym# to find them.
📈 +7% vs. the best specialist tool
🚀 +27% vs. frontier LLMs
💥 2.6B punches way above its weight
#insilicoSOTAFM#
Show more
Tempus trained a foundation model on 1.67M real cancer patients, fusing clinical trajectories with DNA, RNA, and H&E pathology into one patient-state embedding. Overall-survival AUC jumped 0.563 to 0.774, and treatment-benefit ranking improved in 9 of 11 cohorts.
We have argued for years that multimodal models beat curated features in oncology. This is strong evidence at real scale.
Show more
